SCHEMBL13417837

SCHEMBL13417837

COC(=O)CCC1(C)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.52
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 4/20 0.39
CA12 O43570 2/20 0.39
CA14 Q9ULX7 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HSD17B10 Q99714 3/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
RECQL P46063 1/20 0.34
GLA P06280 1/20 0.34
EPHX2 P34913 2/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8252653 0.91 TSHR (0.48) TSHRKMT2AMEN1LMNACA12
SCHEMBL5505303 0.91 TSHR (0.48) TSHRKMT2AMEN1LMNACA12
SCHEMBL14865334 0.90 TSHR (0.46) TSHRKMT2AMEN1LMNACA12
SCHEMBL12561132 0.87 TSHR (0.56) TSHRKMT2AMEN1LMNACA12
SCHEMBL3891515 0.86 GLA (0.44) TSHRKMT2AMEN1LMNACA12
SCHEMBL4702420 0.78 CYP1A2 (0.45) TSHRKMT2AMEN1LMNAKDM4E
SCHEMBL5799860 0.78 TSHR (0.50) TSHRKMT2ALMNAALDH1A1GLA
SCHEMBL15539095 0.77 TSHR (0.52) TSHRKMT2AMEN1LMNACA12
SCHEMBL12542033 0.77 TSHR (0.42) TSHRKMT2AMEN1LMNACA12
SCHEMBL598045 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025224262-A1 COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR MONTE ROSA THERAPEUTICS AG (CH) 2025-10-30 WO disclosed
EP-4608816-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF Monte Rosa Therapeutics AG (CH) 2025-09-03 EP disclosed
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2025-08-21 US disclosed
WO-2024092039-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2024-05-02 WO disclosed
WO-2010039789-A1 SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF CDK2, SKP2, CDK1 TSHR 3902/4885KMT2A 2021/4885MEN1 2754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.